荃信生物-B近3个交易日回购合共54.98万股股份

Core Viewpoint - The company believes its current stock price significantly undervalues its intrinsic value and future growth prospects [1] Summary by Sections - Stock Buyback Announcement - The company has repurchased a total of 549,800 ordinary shares as treasury stock from November 6, 2025, to the date of the announcement [1] - The repurchased shares represent approximately 0.24% of the company's total issued shares as of the announcement date [1] - The total amount involved in the buyback is approximately HKD 11.07 million, excluding commissions and other expenses [1]